EUVIMEDEUVIMED entdecken
FallberichtSystematische ÜbersichtOpen Access · CC BY 4.0

Case Report: Dasatinib-associated chylothorax and occult Bartonella henselae infection in pediatric leukemia: a case report and systematic review

Caili Liu, Ziting Xia, Runxin Lu, Hongye Cai, Chunxi Fu, Shuai Peng, Liang Huang, Xiaoxi Lu

Frontiers in Pharmacology · 28.09.2026 · 17

DOI: 10.3389/fphar.2026.1897328 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 28.09.2026. Verfasst von Caili Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dujiangyan People's Hospital, Dujiangyan City, Sichuan, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chengdu Municipal Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), and chylothorax is one of its rare but serious lymphatic complications. We encountered a 14-year-old boy with Ph + acute lymphoblastic leukemia (ALL) who developed bilateral chylothorax while on dasatinib, with concurrent B. henselae infection (cat-scratch disease) confirmed in the pleural fluid. Prompted by this index case, we performed a systematic review of the literature to explore the potential association between dasatinib-associated chylothorax and Bartonella henselae infection. We searched multiple databases up to March 2026 and identified 24 cases of TKI-associated chylothorax and 11 cases of leukemia-related cat-scratch disease. In our index case, the pleural fluid triglyceride concentration reached 20.40 mmol/L (≈1806 mg/dL)—the highest value reported to date—and mNGS detected B. henselae together with other organisms. After dasatinib was discontinued and the patient received chest drainage, somatostatin, fasting, and anti-infective therapy with doxycycline plus rifampicin, imaging showed near-complete resolution of the effusion, and repeat mNGS confirmed clearance of B. henselae . A formal causality assessment using the Naranjo scale gave a score of 7, indicating a “probable” adverse drug reaction. This case illustrates that lymphatic and infectious complications can coincide in the same patient. Dasatinib-mediated inhibition of Src family kinases may simultaneously impair lymphatic endothelial integrity and suppress T-cell-mediated immune surveillance, thereby facilitating both chylous leakage and opportunistic infection. Clinicians managing paediatric patients receiving long-term dasatinib therapy should remain vigilant for both lymphatic complications and atypical opportunistic infections.

Schlagwörter

Stichwörter der Autor:innen

Bartonella henselaechylothoraxdasatinibdrug safetypediatric leukemia

Autor:innen und Institutionen

  • Dujiangyan People's Hospital, Dujiangyan City, Sichuan, China.
  • Department of Pediatric Hematology and Oncology, West China Second University Hospital, Sichuan University, Chengdu, China.
  • Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.
  • Department of Pharmacy/Evidence-Based Pharmacy Centre, West China Second University Hospital, Sichuan University, Chengdu, China.
  • Children's Medicine Key Laboratory of Sichuan Province, Chengdu, China.
  • NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China.

Förderung

  • Chengdu Municipal Science and Technology Program

Zitieren

APA

Liu, C., Xia, Z., Lu, R., Cai, H., Fu, C., Peng, S., Huang, L., & Lu, X. (2026). Case Report: Dasatinib-associated chylothorax and occult Bartonella henselae infection in pediatric leukemia: a case report and systematic review. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1897328

Vancouver

Liu C, Xia Z, Lu R, Cai H, Fu C, Peng S, et al. Case Report: Dasatinib-associated chylothorax and occult Bartonella henselae infection in pediatric leukemia: a case report and systematic review. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1897328

BibTeX
@article{Liu2026,
  author = {Liu, Caili and Xia, Ziting and Lu, Runxin and Cai, Hongye and Fu, Chunxi and Peng, Shuai and Huang, Liang and Lu, Xiaoxi},
  title = {Case Report: Dasatinib-associated chylothorax and occult Bartonella henselae infection in pediatric leukemia: a case report and systematic review},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1897328}
}
Kostenlos starten →